AU771111B2 - A polynucleotide comprising a ubiquitous chromatin opening element (UCOE) - Google Patents

A polynucleotide comprising a ubiquitous chromatin opening element (UCOE) Download PDF

Info

Publication number
AU771111B2
AU771111B2 AU50534/99A AU5053499A AU771111B2 AU 771111 B2 AU771111 B2 AU 771111B2 AU 50534/99 A AU50534/99 A AU 50534/99A AU 5053499 A AU5053499 A AU 5053499A AU 771111 B2 AU771111 B2 AU 771111B2
Authority
AU
Australia
Prior art keywords
gene
expression
vector
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU50534/99A
Other languages
English (en)
Other versions
AU5053499A (en
Inventor
Michael Antoniou
Robert Crombie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMD Millipore Corp
Original Assignee
ML Laboratories PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815879.3A external-priority patent/GB9815879D0/en
Priority claimed from GBGB9906712.6A external-priority patent/GB9906712D0/en
Priority claimed from GBGB9909494.8A external-priority patent/GB9909494D0/en
Application filed by ML Laboratories PLC filed Critical ML Laboratories PLC
Publication of AU5053499A publication Critical patent/AU5053499A/en
Assigned to ML LABORATORIES PLC reassignment ML LABORATORIES PLC Alteration of Name(s) of Applicant(s) under S113 Assignors: COBRA THERAPEUTICS LIMITED
Publication of AU771111B2 publication Critical patent/AU771111B2/en
Application granted granted Critical
Assigned to Serologicals Investment Company Inc reassignment Serologicals Investment Company Inc Alteration of Name(s) in Register under S187 Assignors: ML LABORATORIES PLC
Assigned to MILLIPORE CORPORATION reassignment MILLIPORE CORPORATION Alteration of Name(s) in Register under S187 Assignors: Serologicals Investment Company Inc
Assigned to EMD Millipre Corporation reassignment EMD Millipre Corporation Request to Amend Deed and Register Assignors: MILLIPORE CORPORATION
Assigned to EMD MILLIPORE CORPORATION reassignment EMD MILLIPORE CORPORATION Request to Amend Deed and Register Assignors: EMD Millipre Corporation
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU50534/99A 1998-07-21 1999-07-21 A polynucleotide comprising a ubiquitous chromatin opening element (UCOE) Expired AU771111B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GBGB9815879.3A GB9815879D0 (en) 1998-07-21 1998-07-21 A polynucleotide
GB9815879 1998-07-21
US10768898P 1998-11-09 1998-11-09
US60/107688 1998-11-09
GBGB9906712.6A GB9906712D0 (en) 1999-03-23 1999-03-23 A polynucleotide
GB9906712 1999-03-23
US12741099P 1999-04-01 1999-04-01
US60/127410 1999-04-01
GBGB9909494.8A GB9909494D0 (en) 1999-04-23 1999-04-23 A plasmid
GB9909494 1999-04-23
US13401699P 1999-05-12 1999-05-12
US60/134016 1999-05-12
PCT/GB1999/002357 WO2000005393A2 (en) 1998-07-21 1999-07-21 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)

Publications (2)

Publication Number Publication Date
AU5053499A AU5053499A (en) 2000-02-14
AU771111B2 true AU771111B2 (en) 2004-03-11

Family

ID=27547316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50534/99A Expired AU771111B2 (en) 1998-07-21 1999-07-21 A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)

Country Status (8)

Country Link
EP (2) EP1098986B1 (https=)
JP (4) JP4220673B2 (https=)
KR (3) KR100795626B1 (https=)
CN (1) CN100365127C (https=)
AU (1) AU771111B2 (https=)
CA (1) CA2333852C (https=)
MX (1) MXPA01000830A (https=)
WO (1) WO2000005393A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
ES2387951T3 (es) * 2001-04-05 2012-10-04 Emd Millipore Corporation Expresión génica mejorada
JP2005500019A (ja) * 2001-04-05 2005-01-06 エムエル ラボラトリーズ ピーエルシー 改良された遺伝子発現
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
HUP0402659A3 (en) 2001-05-30 2008-07-28 Glaxo Group Ltd Chromosome-based platforms
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
PT1600510E (pt) 2001-07-04 2007-06-25 Chromagenics Bv Sequências de adn com actividade anti-repressora.
DE60329366D1 (de) 2002-01-09 2009-11-05 Univ Erasmus Medical Ct Induktierbare transposition beim transgenen organismus mit transposon-vektor
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
ATE524559T1 (de) 2002-12-18 2011-09-15 Chromagenics Bv Methode zur verbesserung der proteinproduktion
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
US9057079B2 (en) 2003-02-01 2015-06-16 Emd Millipore Corporation Expression elements
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
EA014182B1 (ru) 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
KR101271884B1 (ko) 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
ES2384391T3 (es) 2004-11-08 2012-07-04 Chromagenics B.V. Selección de células hospedantes que expresan proteína a altos niveles
GB0504587D0 (en) 2005-03-05 2005-04-13 Ml Lab Plc Vectors comprising guinea pig CMV regulatory elements
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
US7968700B2 (en) 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
JP2010525789A (ja) * 2007-01-08 2010-07-29 ミリポア・コーポレイション １つ又はそれ以上のきょう雑物の低下したレベルの存在下で組換えタンパク質を生産するための細胞培養法
CN104531699B (zh) * 2014-10-09 2017-03-15 河南农业大学 一种增强外源基因表达的猪的ucoe调控元件片段
AU2015367290A1 (en) * 2014-12-16 2017-05-11 Garvan Institute Of Medical Research Sequencing controls
EP3601542A4 (en) * 2017-03-19 2021-01-13 Applied Stemcell, Inc. NEW INTEGRATION SITES AND THEIR USES
CA3056796A1 (en) 2017-04-03 2018-10-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for multiplexed quantitative analysis of cell lineages
US20200385754A1 (en) * 2017-12-07 2020-12-10 Integrity Biosolutions, Llc Engineered ubiquitous chromatin opening elements and uses thereof
US11781146B2 (en) * 2018-05-24 2023-10-10 National University Corporation Hokkaido University Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
SG11202100765UA (en) 2018-08-15 2021-03-30 Illumina Inc Compositions and methods for improving library enrichment
GB2592776B (en) * 2018-10-02 2023-08-16 Univ Leland Stanford Junior Compositions and methods for multiplexed quantitative analysis of cell lineages
WO2020223160A1 (en) * 2019-04-30 2020-11-05 Chan Zuckerberg Biohub, Inc. A novel chromatin-opening element for stable long term gene expression
CN112575031B (zh) * 2019-09-29 2023-04-07 新乡医学院 一种遍在染色质开放表达元件、重组表达载体、表达系统及其制备方法、应用
CN116574735B (zh) * 2023-07-03 2023-11-10 艾米能斯(苏州)生物科技有限公司 一种多核苷酸及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
EP0532525B1 (de) 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue protein-polykation-konjugate
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
GB9109928D0 (en) 1991-05-08 1991-07-03 Interox Chemicals Ltd Thickened compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US5583009A (en) 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0831922A2 (en) 1995-06-08 1998-04-01 Therexsys Limited Improved pharmaceutical compositions for gene therapy
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
AU749113B2 (en) 1997-02-12 2002-06-20 Innovata Plc Compositions and methods for highly efficient transfection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LARSEN ET AL GENOMICS 1992 13:1095-1107 *
ORTIZ ET AL EMBO 1997 16(16):5037-5045 *
SHEWNK ET AL MOL CELL BIOL. 1997 17(10):5856-66 *

Also Published As

Publication number Publication date
JP2009102331A (ja) 2009-05-14
KR100795626B1 (ko) 2008-01-17
EP1098986A2 (en) 2001-05-16
EP1098986B1 (en) 2011-12-28
AU5053499A (en) 2000-02-14
CA2333852A1 (en) 2000-02-03
KR20010083131A (ko) 2001-08-31
JP2008109931A (ja) 2008-05-15
WO2000005393A3 (en) 2000-08-17
CN1334878A (zh) 2002-02-06
WO2000005393A2 (en) 2000-02-03
JP2002522027A (ja) 2002-07-23
CN100365127C (zh) 2008-01-30
HK1035740A1 (en) 2001-12-07
JP4220673B2 (ja) 2009-02-04
EP2348118A1 (en) 2011-07-27
JP2005052149A (ja) 2005-03-03
KR20070108336A (ko) 2007-11-09
CA2333852C (en) 2007-05-29
KR20090117675A (ko) 2009-11-12
MXPA01000830A (es) 2002-06-04

Similar Documents

Publication Publication Date Title
AU771111B2 (en) A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
US8058028B2 (en) Polynucleotide
JP5051738B2 (ja) 人工遍在的クロマチン開放エレメント（ｕｃｏｅ）
US20020094967A1 (en) Polynucleotide
HK1035740B (en) A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
CN101260384A (zh) 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
EP1587934B1 (en) Improved genetic elements providing high levels of expression
EP1856267B1 (en) Vectors comprising novel regulatory elements

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: M.L. LABORATORIES PLC

Free format text: THE FORMER OWNER WAS: COBRA THERAPEUTICS LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired